Xeris Biopharma Holdings Profit Margin

Xeris Biopharma Holdings (XERS) currently reports a profit margin of -5.12% as of June 2026. That compares with -13.08% in the prior-year period — up 60.9% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Xeris Biopharma Holdings's profit margin history and peer comparisons.

Xeris Biopharma Holdings's profit margin increased from -13.08% to -5.12% — a 60.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Xeris Biopharma Holdings's profit margin of -5.12% is lower than the Healthcare sector average of 13.89%. That is roughly 136.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Xeris Biopharma Holdings's current -5.12% should be judged against Healthcare norms (sector average: 13.89%) and against XERS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -5.12%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Xeris Biopharma Holdings, and consider following XERS for alerts when major investors trade the stock.